Drug Trial Radar · NCT02490787
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
Last checked: Nov 20, 2026Latest source record: Jul 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Sep 10, 2015
Primary completion
Oct 14, 2016
Study completion Oct 14, 2016
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jul 7, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted globally. The aim of this trial is to investigate safety, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of concizumab administered subcutaneously to haemophilia A subjects.
Conditions
- Congenital Bleeding Disorder
- Haemophilia A
Interventions
ConcizumabDrug
Administered subcutaneously (s.c., under the skin) at five different dose levels (ranging from 0.25 to 1.5 mg/kg)
placeboDrug
Administered subcutaneously (s.c., under the skin)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of adverse events (AEs)Time frame: From first trial drug administration (day 1) to 11 weeks after the first trial product administration
Locations
34 sites in 15 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Torrance, California
Novo Nordisk Investigational Site
Indianapolis, Indiana
Novo Nordisk Investigational Site
Iowa City, Iowa
Novo Nordisk Investigational Site
Baltimore, Maryland
Novo Nordisk Investigational Site
New York, New York
Novo Nordisk Investigational Site
Portland, Oregon
Novo Nordisk Investigational Site
Houston, Texas
Novo Nordisk Investigational Site
Milwaukee, Wisconsin
Novo Nordisk Investigational Site
Camperdown, New South Wales, Australia
Novo Nordisk Investigational Site
Melbourne, Victoria, Australia
Novo Nordisk Investigational Site
Vienna, Austria
Novo Nordisk Investigational Site
Zagreb, Croatia
Novo Nordisk Investigational Site
Bron, France
Novo Nordisk Investigational Site
Nantes, France
Novo Nordisk Investigational Site
Rennes, France
Novo Nordisk Investigational Site
Berlin, Germany
Novo Nordisk Investigational Site
Duisburg, Germany
Novo Nordisk Investigational Site
Homburg, Germany
Novo Nordisk Investigational Site
Tel HaShomer, Israel
Novo Nordisk Investigational Site
Kuala Lumpur, Malaysia
Novo Nordisk Investigational Site
Kuching, Malaysia
Novo Nordisk Investigational Site
Amsterdam, Netherlands
Novo Nordisk Investigational Site
Nijmegen, Netherlands
Novo Nordisk Investigational Site
Utrecht, Netherlands
Novo Nordisk Investigational Site
Warsaw, Poland
Novo Nordisk Investigational Site
Madrid, Spain
Novo Nordisk Investigational Site
Bangkok, Thailand
Novo Nordisk Investigational Site
Bornova-IZMIR, Turkey (Türkiye)
Novo Nordisk Investigational Site
Dnipropetrovsk, Ukraine
Novo Nordisk Investigational Site
Lviv, Ukraine
Novo Nordisk Investigational Site
London, United Kingdom
Novo Nordisk Investigational Site
London, United Kingdom
Novo Nordisk Investigational Site
Sheffield, United Kingdom
Novo Nordisk Investigational Site
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.